ArticleBlood cancer journal2014

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

M Tobiasson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.